Sparks commentary

Healthcare

Sparks

Heidelberg Pharma (DE: HPHA) doses first patient in Phase I NHL trial
Published by Arron Aatkar, PhD

Heidelberg Pharma has announced that the first patient has been dosed in its Phase I trial assessing Amanitin-based antibody-drug conjugate (ADC) candidate HDP-102 for non-Hodgkin lymphoma (NHL). HDP-102 is the company’s second candidate derived from its proprietary Amanitin-based ADC technology platform to enter the clinic.

The Phase I trial is a multicentre, multinational, open-label study, designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HDP-102 in patients with relapsed or refractory B-cell malignancies, with the additional objective of determining the recommended dose for subsequent clinical development efforts.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free